Stay updated with breaking news from Victora hamamoto. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Acticor Biotech Announces the Completion of Enrollment in its GARDEN Clinical Trial, a COVID-19-induced Acute Respiratory Distress Syndrome Efficacy Study finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Acticor Biotech Announces the Recruitment of the First Patient in its Phase 2 GARDEN Study in COVID-19 related ARDS - GARDEN will enroll 60 patients hospitalized for COVID19 - First Patient included at University Hospital of Strasbourg Acticor Biotech, a clinical stage biotechnology company involved in the acute phase of thrombotic diseases, including acute ischemic stroke, today announces the recruitment of the first patient of its phase 2 GARDEN study to treat COVID-19 related acute respiratory distress syndrome (ARDS) with glenzocimab. GARDEN (clinicaltrials.gov NCT04659109) is a phase 2 study, randomized, double blind, multicenter, placebo controlled, parallel group, exploratory efficacy and safety study of glenzocimab in sars-cov-2-related acute respiratory distress syndrome. GARDEN will enroll 60 patients in France and in Brazil. The Professor Julien POTTECHER, Strasbourg University Hospital, is the Principal Investigator of GARDEN in France. The Professo ....